+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Asia-Pacific Hemodynamic Monitoring Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5175205
  • Report
  • August 2020
  • Region: Asia Pacific
  • 84 Pages
  • Mordor Intelligence


  • Cheetah Medical Inc.
  • Dragerwerk AG & Co. KGaA
  • GE Healthcare
  • Getinge AB
  • ICU Medical Inc.
  • Koninklijke Philips NV
The key factors propelling the Asia-Pacific hemodynamic monitoring market are the increase in the critically ill geriatric population and the rising burden of cardiac disorders and diabetes. According to the economic and social commissions for Asia and Pacific, the percentage of people aged 65 years or older is projected to increase to nearly 23.3% of the population by 2050, in the Asia-Pacific region.
  • Age is associated with a progressive decline in the functional reserve of multiple organ systems. It is, therefore, not surprising that elderly patients may utilize a disproportionate share of healthcare resources, as approximately 92% of older adults have at least one chronic disease, and 77% have at least two. Early and effective hemodynamic management with fluid therapy and administration of vasoactive drugs to maintain vital organ perfusion and oxygen delivery is mandatory in critically ill patients. This is expected to increase the demand for hemodynamic monitoring, which, in turn, may drive the Asia-Pacific hemodynamic monitoring market.
  • The market is also propelling due to the increase in the number of reported cases of lifestyle-related diseases, like diabetes, obesity, COPD, and cardiac myopathy, among many others, which require medical monitoring by healthcare professionals, in the Asia-Pacific region. Therefore, the rise in the prevalence of many diseases is directly proportional to the growth of the hemodynamic monitoring market.

Key Market Trends

The Non-invasive Monitoring Systems Segment is Expected to Grow Fastest Over the Forecast Period

Invasive monitoring systems dominate the Asia-Pacific hemodynamic monitoring market, as they provide critical care, allow detailed determinations of cardiorespiratory variables, and are used for the effective preoperative assessment of high-risk patients.

The non-invasive hemodynamic monitoring systems segment is expected to register a good CAGR over the forecast period. In the coming years, the non-invasive hemodynamic monitoring system market is expected to witness the highest growth, with China, Japan, and India positioned as growth engines. According to the American Diabetic Association, around 60% of the world’s diabetic population lives in Asia. According to the journal of diabetology.org, the number of people with diabetes in Southeast Asia in 2017 was 80 million, and it is expected to increase to 151 million by 2045. There is high growth in the aging population and a high prevalence of diabetes and cardiac diseases, which have helped drive the non-invasive hemodynamic monitoring system market.

Competitive Landscape

The Asia-Pacific hemodynamic monitoring market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown


  • Cheetah Medical Inc.
  • Dragerwerk AG & Co. KGaA
  • GE Healthcare
  • Getinge AB
  • ICU Medical Inc.
  • Koninklijke Philips NV

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in the Critically-ill, Chronic Disease Patient Population
4.2.2 Technological Advancements by Medical Devices Companies
4.3 Market Restraints
4.3.1 Increased Incidences of Complications Associated with Invasive Monitoring Systems
4.3.2 Stringent FDA Guidelines for Approval of New Systems
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5.1 By System
5.1.1 Minimally Invasive Monitoring Systems
5.1.2 Invasive Monitoring Systems
5.1.3 Non-invasive Monitoring Systems
5.2 By Application
5.2.1 Laboratory-based Monitoring Systems
5.2.2 Home-based Monitoring Systems
5.2.3 Hospital-based Monitoring Systems
5.3 Geography
5.3.1 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
6.1 Company Profiles
6.1.1 Edwards Life Sciences Corporation
6.1.2 LiDCO Group PLC
6.1.3 ICU Medical Inc.
6.1.4 Schwarzer Cardiotek GmbH
6.1.5 Koninklijke Philips NV
6.1.6 Cheetah Medical Inc.
6.1.7 Getinge AB
6.1.8 GE Healthcare
6.1.9 Dragerwerk AG & Co. KGaA
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Edwards Life Sciences Corporation
  • LiDCO Group PLC
  • ICU Medical Inc.
  • Schwarzer Cardiotek GmbH
  • Koninklijke Philips NV
  • Cheetah Medical Inc.
  • Getinge AB
  • GE Healthcare
  • Dragerwerk AG & Co. KGaA
Note: Product cover images may vary from those shown